AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24768960 — intervention group
Group type: COMPARATOR
Intervention: Ablation
Number of subjects: 0
Study 22279232 — intervention group
Group type: EXPERIMENTAL
Intervention: Nociceptive stimulus applied after presentation of neutral scenes
Number of subjects: 0
Study 19634167 — intervention group
Group type: EXPERIMENTAL
Intervention: Trospium chloride XR
Number of subjects: 1165
Study 19634167 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1165
Study 18622147 — intervention group
Group type: EXPERIMENTAL
Intervention: peg‐interferon plus ribavirin combined therapy
Number of subjects: 44
Study 16026361 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (30‐45 mg/day, n = 38)
Number of subjects: 114
Study 16026361 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (750 mg/day, n = 39)
Number of subjects: 114
Study 16026361 — intervention group
Group type: EXPERIMENTAL
Intervention: Glimepiride (1.0‐2.0 mg/day, n = 37)
Number of subjects: 114
Study 12361442 — intervention group
Group type: EXPERIMENTAL
Intervention: CHILD Profile
Number of subjects: 2472
Study 12361442 — intervention group
Group type: EXPERIMENTAL
Intervention: Other computerized systems
Number of subjects: 2472
Study 12361442 — intervention group
Group type: COMPARATOR
Intervention: Family physicians
Number of subjects: 2472
Study 12361442 — intervention group
Group type: COMPARATOR
Intervention: Private physicians
Number of subjects: 2472
Study 12361442 — intervention group
Group type: COMPARATOR
Intervention: Physicians taking fewest opportunities to immunize
Number of subjects: 2472
Study 12361442 — intervention group
Group type: COMPARATOR
Intervention: Physicians in areas with CHILD Profile marketing activity
Number of subjects: 2472
Study 12361442 — intervention group
Group type: COMPARATOR
Intervention: Physicians in areas with little or no registry activity
Number of subjects: 2472
Study 12361442 — intervention group
Group type: EXPERIMENTAL
Intervention: Physicians with computerized systems
Number of subjects: 2472
Study 12361442 — intervention group
Group type: COMPARATOR
Intervention: Physicians without computerized systems
Number of subjects: 2472
Study 10408844 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alpha 300 IU kg(‐1) subcutaneously three times a week
Number of subjects: 130
Study 10408844 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alpha 150 IU kg(‐1) subcutaneously three times a week
Number of subjects: 130
Study 10408844 — intervention group
Group type: COMPARATOR
Intervention: No additional treatment (control group)
Number of subjects: 130
Study 8543404 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg/m2 AS101 combined with carboplatin and VP-16
Number of subjects: 58
Study 8543404 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 58
Study 2056971 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 646
Study 2056971 — intervention group
Group type: COMPARATOR
Intervention: Prednisone
Number of subjects: 646
Study 2056971 — intervention group
Group type: EXPERIMENTAL
Intervention: IT MTX plus cranial radiation
Number of subjects: 646
Study 2056971 — intervention group
Group type: COMPARATOR
Intervention: IT MTX alone
Number of subjects: 646
Study 6847362 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric exclusion (bypass)
Number of subjects: 100
Study 6847362 — intervention group
Group type: COMPARATOR
Intervention: Gastric partition (gastroplasty)
Number of subjects: 100
Study 31475791 — intervention group
Group type: EXPERIMENTAL
Intervention: Drainage ball with low negative pressure
Number of subjects: 60
Study 31475791 — intervention group
Group type: COMPARATOR
Intervention: Chest tube with water‐sealed bottle
Number of subjects: 60
Study 29049180 — intervention group
Group type: EXPERIMENTAL
Intervention: Care intervention (dietary, exercise, and psychology interventions on the basis of conventional care)
Number of subjects: 126
Study 29049180 — intervention group
Group type: COMPARATOR
Intervention: Conventional care (control group)
Number of subjects: 126
Study 25256627 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive working memory (WM) training
Number of subjects: 121
Study 25256627 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive cognitive flexibility-training
Number of subjects: 121
Study 25256627 — intervention group
Group type: COMPARATOR
Intervention: Non-adaptive control training (mock-training)
Number of subjects: 121
Study 24968008 — intervention group
Group type: EXPERIMENTAL
Intervention: Right rTMS
Number of subjects: 48
Study 24968008 — intervention group
Group type: COMPARATOR
Intervention: Left rTMS
Number of subjects: 48
Study 24968008 — intervention group
Group type: COMPARATOR
Intervention: Sham
Number of subjects: 48
Study 22172646 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole (LET) for 2.5 years
Number of subjects: 1215
Study 22172646 — intervention group
Group type: COMPARATOR
Intervention: Letrozole (LET) for 5 years
Number of subjects: 1215
Study 22172646 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole (LET)
Number of subjects: 1215
Study 19168237 — intervention group
Group type: EXPERIMENTAL
Intervention: ADMA plasma levels measured by high-performance liquid chromatography
Number of subjects: 84
Study 19168237 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial infusion of acetylcholine (ACh)
Number of subjects: 84
Study 19168237 — intervention group
Group type: EXPERIMENTAL
Intervention: Homeostasis model assessment (HOMA)
Number of subjects: 84
Study 19168237 — intervention group
Group type: EXPERIMENTAL
Intervention: ADMA and gender
Number of subjects: 84
Study 17571296 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative intraperitoneal local anaesthesia (50 ml 0.5 per cent lidocaine)
Number of subjects: 133
Study 17571296 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative intraperitoneal local anaesthesia (50 ml 0.5 per cent lidocaine)
Number of subjects: 133
Study 17571296 — intervention group
Group type: COMPARATOR
Intervention: Placebo solution (50 ml 0.9 per cent saline)
Number of subjects: 133
Study 16135164 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg terbutaline
Number of subjects: 16
Study 16135164 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 16135164 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg terbutaline after withdrawal from beta(2) agonists
Number of subjects: 16
Study 11814533 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 75
Study 11814533 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 75
Study 11814533 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 10411700 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal hematocrit (42 +/- 3%)
Number of subjects: 28
Study 10411700 — intervention group
Group type: COMPARATOR
Intervention: Anemic hematocrit (30 +/- 3%)
Number of subjects: 28
Study 7550179 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifabutin 300 mg/day
Number of subjects: 1104
Study 7550179 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1104
Study 2029659 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (2000 IU 12 hours prior to surgery) and Vitamin C (2 g on the day of operation)
Number of subjects: 20
Study 2029659 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E and Vitamin C
Number of subjects: 20
Study 2029659 — intervention group
Group type: COMPARATOR
Intervention: Control (no vitamin E or C treatment)
Number of subjects: 20
Study 6135725 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose propranolol (22 +/- 4 mg four times daily)
Number of subjects: 12
Study 6135725 — intervention group
Group type: COMPARATOR
Intervention: Control group (no drug)
Number of subjects: 12
Study 31573893 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir 400 mg/Daclatasvir 60 mg
Number of subjects: 100
Study 31573893 — intervention group
Group type: COMPARATOR
Intervention: Sofosbuvir 400 mg/Ledipasvir 90 mg
Number of subjects: 100
Study 30942258 — intervention group
Group type: EXPERIMENTAL
Intervention: Miltefosine 1.3‐2 mg/kg/day for 28 days
Number of subjects: 40
Study 30942258 — intervention group
Group type: COMPARATOR
Intervention: Meglumine antimoniate (N‐MA) 20 mg SbV/kg/day for 30 days
Number of subjects: 40
Study 30942258 — intervention group
Group type: EXPERIMENTAL
Intervention: Miltefosine
Number of subjects: 40
Study 30942258 — intervention group
Group type: COMPARATOR
Intervention: Meglumine antimoniate (N‐MA)
Number of subjects: 40
Study 28872914 — intervention group
Group type: EXPERIMENTAL
Intervention: Edaravone
Number of subjects: 0
Study 28872914 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 27194863 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine 0.12% (CHX) preprocedural rinse
Number of subjects: 45
Study 27194863 — intervention group
Group type: EXPERIMENTAL
Intervention: High volume evacuator (HVE)
Number of subjects: 45
Study 27194863 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of CHX (0.12%) and HVE
Number of subjects: 45
Study 27194863 — intervention group
Group type: COMPARATOR
Intervention: Ultrasonic scaling without intervention (Control Group A)
Number of subjects: 45
Study 24637126 — intervention group
Group type: EXPERIMENTAL
Intervention: Rasagiline 1 mg/day
Number of subjects: 876
Study 24637126 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 876
Study 19463332 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative medical management
Number of subjects: 8225
Study 19463332 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 8225
Study 19463332 — intervention group
Group type: COMPARATOR
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 8225
Study 15150185 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertapenem 1 g once a day
Number of subjects: 850
Study 15150185 — intervention group
Group type: COMPARATOR
Intervention: Ceftriaxone 1 g once a day
Number of subjects: 850
Study 15150185 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertapenem and Ceftriaxone
Number of subjects: 850
Study 11030869 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical trauma under general anesthesia
Number of subjects: 15
Study 9302369 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) administration
Number of subjects: 46
Study 9302369 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment for the first 6 months followed by GH administration for the next 6 months
Number of subjects: 46
Study 9302369 — intervention group
Group type: EXPERIMENTAL
Intervention: GH administration
Number of subjects: 46
Study 8287572 — intervention group
Group type: EXPERIMENTAL
Intervention: Suramin i.v. (for haemolymphatic sleeping sickness)
Number of subjects: 65
Study 8287572 — intervention group
Group type: EXPERIMENTAL
Intervention: Melarsoprol (for cerebral sleeping sickness)
Number of subjects: 65
Study 8287572 — intervention group
Group type: EXPERIMENTAL
Intervention: Suramin i.v. / Melarsoprol (during treatment)
Number of subjects: 65
Study 2882736 — intervention group
Group type: COMPARATOR
Intervention: Imipramine hydrochloride
Number of subjects: 0
Study 2882736 — intervention group
Group type: EXPERIMENTAL
Intervention: In vivo exposure
Number of subjects: 0
Study 2882736 — intervention group
Group type: COMPARATOR
Intervention: Office-based behavioral therapy
Number of subjects: 0
Study 2882736 — intervention group
Group type: EXPERIMENTAL
Intervention: In vivo exposure without imipramine
Number of subjects: 0
Study 2882736 — intervention group
Group type: EXPERIMENTAL
Intervention: In vivo exposure with imipramine
Number of subjects: 0
Study 30801744 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized gonadotropin dosing based on AMH levels
Number of subjects: 1326
Study 28433473 — intervention group
Group type: EXPERIMENTAL
Intervention: HIGH resistance training (8 males, 10 females, 2 × 10–15 repetitions at 80% 1RM)
Number of subjects: 56
Study 28433473 — intervention group
Group type: COMPARATOR
Intervention: LOW resistance training (9 males, 10 females, 1 × 80–100 repetitions at 20% 1RM)
Number of subjects: 56
Study 28433473 — intervention group
Group type: COMPARATOR
Intervention: LOW+ resistance training (9 males, 10 females, 1 × 60 repetitions at 20% 1RM followed by 1 × 10–20 repetitions at 40% 1RM)
Number of subjects: 56
Study 28433473 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups post-exercise
Number of subjects: 56
Study 28031039 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention training using novel eye‐tracking technology and gaze‐contingent training paradigms, nine weekly home‐based sessions
Number of subjects: 50
Study 28031039 — intervention group
Group type: COMPARATOR
Intervention: Non‐gaze‐contingent age‐appropriate videos, nine weekly home visits
Number of subjects: 50
Study 24433822 — intervention group
Group type: EXPERIMENTAL
Intervention: FAST parent programme (First‐aid Advice and Safety Training)
Number of subjects: 96
Study 24433822 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal care)
Number of subjects: 96
Study 22487033 — intervention group
Group type: EXPERIMENTAL
Intervention: Reinforcement Learning (RL) with integrated Working Memory (WM) model
Number of subjects: 0
Study 22487033 — intervention group
Group type: EXPERIMENTAL
Intervention: COMT gene influence on WM capacity
Number of subjects: 0
Study 22487033 — intervention group
Group type: EXPERIMENTAL
Intervention: GPR6 gene influence on RL learning rate
Number of subjects: 0
Study 19038848 — intervention group
Group type: EXPERIMENTAL
Intervention: atorvastatin (10 mg/d) for 6 weeks
Number of subjects: 25
Study 19038848 — intervention group
Group type: EXPERIMENTAL
Intervention: torcetrapib/atorvastatin (60/10 mg/d) for 6 weeks
Number of subjects: 25
Study 19038848 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (healthy controls)
Number of subjects: 25
Study 19038848 — intervention group
Group type: EXPERIMENTAL
Intervention: CETP inhibition
Number of subjects: 25
Study 17503980 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (25‐200 mg/day)
Number of subjects: 169
Study 17503980 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 169
Study 15550799 — intervention group
Group type: EXPERIMENTAL
Intervention: PHQ-9
Number of subjects: 434
Study 11136908 — intervention group
Group type: EXPERIMENTAL
Intervention: CADASIL individuals
Number of subjects: 29
Study 11136908 — intervention group
Group type: EXPERIMENTAL
Intervention: Nondisabled CADASIL individuals (Rankin=0, n=21)
Number of subjects: 29
Study 11136908 — intervention group
Group type: EXPERIMENTAL
Intervention: Disabled CADASIL individuals
Number of subjects: 29
Study 9812660 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonic dialysis therapy with Chinese herbal medicine (from third day to eighth day)
Number of subjects: 125
Study 9812660 — intervention group
Group type: COMPARATOR
Intervention: Combined dihydroetorphine (DHE) and methadon therapy
Number of subjects: 125
Study 8588492 — intervention group
Group type: EXPERIMENTAL
Intervention: Periconceptional multivitamin supplementation (including 0.8 mg folic acid)
Number of subjects: 5502
Study 8588492 — intervention group
Group type: COMPARATOR
Intervention: Placebo-like trace-element control group
Number of subjects: 5502
Study 3662586 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (BUD) 200 micrograms twice daily
Number of subjects: 10
Study 3662586 — intervention group
Group type: COMPARATOR
Intervention: Beclomethasone dipropionate (BDP) 200 micrograms twice daily
Number of subjects: 10
Study 28892558 — intervention group
Group type: EXPERIMENTAL
Intervention: 18 mg of selonsertib orally once daily for 24 weeks
Number of subjects: 72
Study 28892558 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg of selonsertib orally once daily for 24 weeks
Number of subjects: 72
Study 28892558 — intervention group
Group type: COMPARATOR
Intervention: Simtuzumab alone
Number of subjects: 72
Study 26909323 — intervention group
Group type: EXPERIMENTAL
Intervention: Psilocybin
Number of subjects: 0
Study 26909323 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 24699924 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified mini-Hardinge approach
Number of subjects: 51
Study 24699924 — intervention group
Group type: COMPARATOR
Intervention: Standard approach
Number of subjects: 51
Study 22644776 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab plus capecitabine/irinotecan
Number of subjects: 0
Study 22644776 — intervention group
Group type: COMPARATOR
Intervention: Cetuximab plus capecitabine/oxaliplatin
Number of subjects: 0
Study 22644776 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab (first-cycle rash observed)
Number of subjects: 0
Study 22644776 — intervention group
Group type: EXPERIMENTAL
Intervention: No Cet-ST
Number of subjects: 0
Study 20494665 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid, vitamin B(12), and vitamin B(6)
Number of subjects: 348
Study 20494665 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 348
Study 20494665 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid/vitamin B(12)
Number of subjects: 348
Study 20494665 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B(6)
Number of subjects: 348
Study 19020693 — intervention group
Group type: EXPERIMENTAL
Intervention: Very early mobilization (within 24 hours of stroke)
Number of subjects: 71
Study 19020693 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 71
Study 17089238 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary care (MDC)
Number of subjects: 160
Study 17089238 — intervention group
Group type: COMPARATOR
Intervention: Routine care (RC)
Number of subjects: 160
Study 14616453 — intervention group
Group type: EXPERIMENTAL
Intervention: High-energy transurethral microwave thermotherapy (HE-TUMT)
Number of subjects: 144
Study 14616453 — intervention group
Group type: COMPARATOR
Intervention: Transurethral resection of the prostate (TURP)
Number of subjects: 144
Study 10649829 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan (6 mg SQ)
Number of subjects: 11
Study 10649829 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 8629587 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin 40 mg/day
Number of subjects: 0
Study 8629587 — intervention group
Group type: COMPARATOR
Intervention: Pravastatin 40 mg/day
Number of subjects: 0
Study 1424176 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyproterone acetate (CPA, 50 mg once daily from Day 5 to Day 15) and ethinyl oestradiol (EE2, 30 micrograms once daily from Day 5 to Day 24 of the menstrual cycle)
Number of subjects: 40
Study 1424176 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 40
Study 4096742 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal-release 10 mg nifedipine soft gelatine capsule (Pidilat)
Number of subjects: 12
Study 4096742 — intervention group
Group type: COMPARATOR
Intervention: Marketed product (control)
Number of subjects: 12
Study 4096742 — intervention group
Group type: EXPERIMENTAL
Intervention: Both preparations
Number of subjects: 12
Study 30836964 — intervention group
Group type: EXPERIMENTAL
Intervention: Community health worker (CHW) intervention
Number of subjects: 268
Study 30836964 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 268
Study 30219466 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided imagery (six times a week for four weeks)
Number of subjects: 70
Study 26751635 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal (IT) and intramuscular (IM) administration of autologous MSC‐NTF cells
Number of subjects: 26
Study 25222490 — intervention group
Group type: EXPERIMENTAL
Intervention: Processed hamburger meat meal (M-meal)
Number of subjects: 100
Study 25222490 — intervention group
Group type: COMPARATOR
Intervention: Vegan meal (V-meal)
Number of subjects: 100
Study 21856047 — intervention group
Group type: EXPERIMENTAL
Intervention: Leisure activity (high levels)
Number of subjects: 4303
Study 21856047 — intervention group
Group type: EXPERIMENTAL
Intervention: Leisure activity (low levels)
Number of subjects: 4303
Study 21856047 — intervention group
Group type: EXPERIMENTAL
Intervention: APOE ε4 carriers
Number of subjects: 4303
Study 21856047 — intervention group
Group type: EXPERIMENTAL
Intervention: APOE ε4 noncarriers
Number of subjects: 4303
Study 21856047 — intervention group
Group type: EXPERIMENTAL
Intervention: APOE ε4 carriers and noncarriers (after adjustment for demographic and health factors)
Number of subjects: 4303
Study 20219584 — intervention group
Group type: EXPERIMENTAL
Intervention: GaAlAs laser therapy (P = 100 mW, lambda = 830 nm, Ø = 0.06 cm(2), applied in 8 sessions with intervals of 48 hours)
Number of subjects: 13
Study 20219584 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 6)
Number of subjects: 13
Study 17676201 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (0.02 mg kg‐1) + Propofol (0.2 mg kg‐1) + Fentanyl (1 microgram kg‐1)
Number of subjects: 0
Study 17676201 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (0.02 mg kg‐1)
Number of subjects: 0
Study 17676201 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (0.02 mg kg‐1) + Propofol (0.2 mg kg‐1)
Number of subjects: 0
Study 17676201 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (0.02 mg kg‐1) + Fentanyl (1 microgram kg‐1)
Number of subjects: 0
Study 15789787 — intervention group
Group type: EXPERIMENTAL
Intervention: Same admission colostomy closure (SACC)
Number of subjects: 60
Study 15789787 — intervention group
Group type: COMPARATOR
Intervention: Conventional delayed colostomy closure (CDCC)
Number of subjects: 60
Study 11902739 — intervention group
Group type: COMPARATOR
Intervention: 10 mL/kg red blood cells
Number of subjects: 0
Study 11902739 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mL/kg red blood cells
Number of subjects: 0
Study 9820444 — intervention group
Group type: EXPERIMENTAL
Intervention: Silver ring device
Number of subjects: 195
Study 9820444 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 195
Study 7714065 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 IU vitamin D3 per day
Number of subjects: 348
Study 7714065 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 348
Study 2523785 — intervention group
Group type: EXPERIMENTAL
Intervention: NPH insulin (12 units injected subcutaneously)
Number of subjects: 6
Study 414344 — intervention group
Group type: EXPERIMENTAL
Intervention: Floctafenine 1.6 g daily
Number of subjects: 48
Study 414344 — intervention group
Group type: EXPERIMENTAL
Intervention: Soluble aspirin 4.0 g daily
Number of subjects: 48